BBC Russian

PGS Sample Set (PSS): PSS009633

Sample #1

Phenotype	None
Sample Ancestry	African American or Afro-Caribbean

Sample Numbers

Total number	10,875 individuals
Detailed numbers	5,505 cases (50.62%) 5,370 controls 100.0% Male samples
Number of Cohort(s)	4

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
BPC3	The National Cancer Institute Breast and Prostate Cancer Cohort Consortium	—
CGEMS	National Cancer Institute Cancer Genetic Markers of Susceptibility	—
Ghana	Ghana	—
PEGASUS	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin	—

Additional information

GENEVA, ICPCG, ONCO

Sample #2

Phenotype	None
Sample Ancestry	Asian unspecified

Sample Numbers

Total number	3,057 individuals
Detailed numbers	1,574 cases (51.49%) 1,483 controls 100.0% Male samples
Number of Cohort(s)	4

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
BPC3	The National Cancer Institute Breast and Prostate Cancer Cohort Consortium	—
CGEMS	National Cancer Institute Cancer Genetic Markers of Susceptibility	—
Ghana	Ghana	—
PEGASUS	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin	—

Additional information

GENEVA, ICPCG, ONCO

Sample #3

Phenotype	None
Sample Ancestry	European

Sample Numbers

Total number	91,623 individuals
Detailed numbers	54,564 cases (59.55%) 37,059 controls 100.0% Male samples
Number of Cohort(s)	4

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
BPC3	The National Cancer Institute Breast and Prostate Cancer Cohort Consortium	—
CGEMS	National Cancer Institute Cancer Genetic Markers of Susceptibility	—
Ghana	Ghana	—
PEGASUS	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin	—

Additional information

GENEVA, ICPCG, ONCO

Sample #4

Phenotype	None
Sample Ancestry	Sub-Saharan African (Ghanaian)

Sample Numbers

Total number	913 individuals
Detailed numbers	461 cases (50.49%) 452 controls 100.0% Male samples
Number of Cohort(s)	4

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
BPC3	The National Cancer Institute Breast and Prostate Cancer Cohort Consortium	—
CGEMS	National Cancer Institute Cancer Genetic Markers of Susceptibility	—
Ghana	Ghana	—
PEGASUS	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin	—

Additional information

GENEVA, ICPCG, ONCO

Sample #5

Phenotype	None
Sample Ancestry	Hispanic or Latin American

Sample Numbers

Total number	4,238 individuals
Detailed numbers	2,170 cases (51.2%) 2,068 controls 100.0% Male samples
Number of Cohort(s)	4

Sample distribution

Sample gender distribution

Cohort(s)

Cohort Short Name	Cohort Full Name	Previous/other/additional names (e.g. sub-cohorts)
BPC3	The National Cancer Institute Breast and Prostate Cancer Cohort Consortium	—
CGEMS	National Cancer Institute Cancer Genetic Markers of Susceptibility	—
Ghana	Ghana	—
PEGASUS	Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin	—